|
WO2021003374A2
|
|
Host systems comprising inhibitors of a gene-editing protein for production of viral vectors
|
|
WO2020257590A1
|
|
Production of vectors using phage origin of replication
|
|
WO2020146381A2
|
|
A method of treating cystic fibrosis
|
|
WO2020102667A2
|
|
Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
|
|
WO2020102645A1
|
|
Therapeutic adeno-associated virus for treating pompe disease
|
|
WO2019246544A2
|
|
Vectors for gene delivery that persist within cells
|
|
CA3095127A1
|
|
Liver tropic recombinant aav6 vectors that evade neutralization
|
|
WO2015148454A1
|
|
Optimized and modified factor viii genes for gene therapy
|
|
WO2014159546A1
|
|
Modified soluble vegf receptor-1 genes and vectors for gene therapy
|
|
EP2037892A2
|
|
Modified factor viii and factor ix genes and vectors for gene therapy
|
